<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850718</url>
  </required_header>
  <id_info>
    <org_study_id>SIL-003</org_study_id>
    <nct_id>NCT02850718</nct_id>
  </id_info>
  <brief_title>A Pivotal Study of the Bioequivalence of Oral Viagra® and a Test Sublingual Sildenafil Wafer</brief_title>
  <official_title>A Pivotal Study of the Bioequivalence of Oral Viagra® and a Test Sublingual Sildenafil Wafer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iX Biopharma Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Linear Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>iX Biopharma Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparative bioequivalence study in 48 healthy male volunteers of oral Viagra and a test&#xD;
      sublingual sildenafil wafer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy volunteers will complete two inpatient study periods and receive either sublingual&#xD;
      wafer sildenafil or oral sildenafil. Plasma samples and adverse events will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sildenafil plasma concentrations</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-related adverse events</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Period 1: Sublingual wafer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive receive a single dose of 50 mg sublingual sildenafil followed by plasma sampling for 14 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2: Oral comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receive a single dose of 50 mg oral sildenafil (Viagra) followed by plasma sampling for 14 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual Sildenafil</intervention_name>
    <description>50 mg sildenafil sublingual wafer.</description>
    <arm_group_label>Period 1: Sublingual wafer</arm_group_label>
    <other_name>Pheonix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Sildenafil</intervention_name>
    <description>50 mg oral sildenafil (Viagra)</description>
    <arm_group_label>Period 2: Oral comparator</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily provides signed, written, and dated informed consent prior to any&#xD;
             study-specific procedures.&#xD;
&#xD;
          2. Healthy male volunteers aged 18-50 years inclusive.&#xD;
&#xD;
          3. In good general health without clinically significant haematological, cardiac,&#xD;
             respiratory, renal, endocrine, gastrointestinal, psychiatric, hepatic, or malignant&#xD;
             disease, as determined by the Principal Investigator.&#xD;
&#xD;
          4. Sufficient access for venous cannulation to withdraw blood as per the study design.&#xD;
&#xD;
          5. Body mass index (BMI) of ≥19 to ≤ 30kg/m2 (inclusive).&#xD;
&#xD;
          6. Participant is deemed able to read and understand English in order to communicate with&#xD;
             research staff and complete protocol required questionnaires and forms.&#xD;
&#xD;
          7. Able to refrain from smoking while at the research unit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Past history of hypersensitivity to sildenafil, any of its excipients, or severe&#xD;
             allergic or anaphylactic reaction to any other drug.&#xD;
&#xD;
          2. A medical condition that, in the opinion of the Investigator, may adversely impact the&#xD;
             participant's ability to complete the study, including but not limited to:&#xD;
&#xD;
               1. History of priapism;&#xD;
&#xD;
               2. History of easy fainting or symptomatic postural hypotension;&#xD;
&#xD;
               3. Standing or supine systolic blood pressure &lt; 90mmHg or diastolic blood pressure &lt;&#xD;
                  50mm Hg or postural drop of &gt;30mm Hg;&#xD;
&#xD;
               4. History of myocardial infarction or clinically significant cardiac disease&#xD;
                  including cardiac arrhythmia;&#xD;
&#xD;
               5. History of retinitis pigmentosa or optic neuropathy or other risk factors of&#xD;
                  non-arteritic anterior ischaemic optic neuropathy (NAION);&#xD;
&#xD;
               6. History or evidence of hypertension - defined as three BP readings (at rest)&#xD;
                  within 15 minutes of systolic blood pressure ≥140 mm Hg or diastolic blood&#xD;
                  pressure ≥90 mmHg. Note: serial blood pressure readings are only required if the&#xD;
                  initial reading is elevated;&#xD;
&#xD;
               7. Anaemia (haemoglobin &lt; lower limit of normal for sex).&#xD;
&#xD;
          3. Clinically significant 12-lead ECG abnormalities at the screening visit as determined&#xD;
             by the Investigator.&#xD;
&#xD;
          4. Concomitant consumption of any other medication regularly, with the exception of&#xD;
             vitamins or minerals.&#xD;
&#xD;
          5. Consumption of drugs with either enzyme-inducing properties, such as rifampicin and St&#xD;
             John's Wort, within 3 weeks prior to the initial dose of study drug and throughout the&#xD;
             treatment phase or CYP3A4 inhibitors, such as erythromycin and clarithromycin, within&#xD;
             5 half-lives prior to the initial dose of study drug and throughout the treatment&#xD;
             phase.&#xD;
&#xD;
          6. Previous known or suspected drug abuse (including analgesic drugs or tranquilizers) or&#xD;
             dependence, as defined by DSM-IV, or history of alcohol abuse or excessive intake of&#xD;
             alcohol, defined as regular weekly intake of &gt;15 units for men and &gt;10 units for women&#xD;
             (1 unit= 25ml spirits,125ml wine, 250ml beer or lager).&#xD;
&#xD;
          7. Positive results on the urine drug screen indicative of illicit drug abuse or&#xD;
             inconsistent with medication history, or alcohol breath test indicative of alcohol&#xD;
             abuse.&#xD;
&#xD;
          8. History of hepatitis B or C, or other forms of non-infectious liver disease.&#xD;
&#xD;
          9. Clinically significant abnormalities in clinical chemistry, haematology, urinalysis,&#xD;
             or serology results at screening that, in the opinion of the Investigator, puts the&#xD;
             volunteer at risk for study participation.&#xD;
&#xD;
         10. Clinically significant plasma AST, ALT and ALP tests (defined as ≥1.5 times the upper&#xD;
             limit of normal).&#xD;
&#xD;
         11. Positive serology for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or&#xD;
             hepatitis C virus (HCV) infection at screening.&#xD;
&#xD;
         12. Prevalent abnormality in the oral cavity which may alter sublingual drug absorption&#xD;
             (e.g. recurrent oral ulceration, lichen planus, or xerostomia).&#xD;
&#xD;
         13. Any other condition which, in the opinion of the Investigator, makes the volunteer&#xD;
             unsuitable for the study.&#xD;
&#xD;
         14. Unwillingness or inability to comply with the requirements of this protocol, including&#xD;
             the presence of any condition (physical, mental, or social) that is likely to affect&#xD;
             the participant's ability to return for follow up visits on schedule.&#xD;
&#xD;
         15. Member or relative of study staff or the Sponsor directly involved in the study.&#xD;
&#xD;
         16. Previous participation in this study.&#xD;
&#xD;
         17. Has received another investigational agent or new chemical entity (defined as a&#xD;
             compound which has not been approved for marketing) within 30 days prior to the&#xD;
             Screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

